Vanguard Group
ACRS icon

Vanguard Group’s Aclaris Therapeutics ACRS Stock Holding History

Vanguard Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$19.6M Sell
6,502,080
-13,378
-0.2% -$33.8K ﹤0.01% 2626
2025
Q3 		$12.4M Sell
6,515,458
-146,605
-2% -$256K ﹤0.01% 2859
2025
Q2 		$9.46M Buy
6,662,063
+1,691,809
+34% +$2.29M ﹤0.01% 2933
2025
Q1 		$7.6M Buy
4,970,254
+644,991
+15% +$1.38M ﹤0.01% 2993
2024
Q4 		$10.7M Sell
4,325,263
-360,235
-8% -$896K ﹤0.01% 2915
2024
Q3 		$5.39M Sell
4,685,498
-2,053
-0% -$2.52K ﹤0.01% 3246
2024
Q2 		$5.16M Sell
4,687,551
-242,224
-5% -$285K ﹤0.01% 3249
2024
Q1 		$6.11M Buy
4,929,775
+207,418
+4% +$247K ﹤0.01% 3217
2023
Q4 		$4.96M Buy
4,722,357
+1,359,311
+40% +$4.15M ﹤0.01% 3295
2023
Q3 		$23M Buy
3,363,046
+33,482
+1% +$286K ﹤0.01% 2492
2023
Q2 		$34.5M Buy
3,329,564
+137,138
+4% +$1.24M ﹤0.01% 2356
2023
Q1 		$25.8M Buy
3,192,426
+70,171
+2% +$891K ﹤0.01% 2479
2022
Q4 		$49.2M Buy
3,122,255
+190,546
+6% +$3.07M ﹤0.01% 2197
2022
Q3 		$46.1M Buy
2,931,709
+118,024
+4% +$1.86M ﹤0.01% 2224
2022
Q2 		$39.3M Buy
2,813,685
+84,865
+3% +$1.19M ﹤0.01% 2307
2022
Q1 		$47M Buy
2,728,820
+10,713
+0.4% +$146K ﹤0.01% 2336
2021
Q4 		$39.5M Buy
2,718,107
+39,167
+1% +$593K ﹤0.01% 2484
2021
Q3 		$48.2M Buy
2,678,940
+112,169
+4% +$1.8M ﹤0.01% 2379
2021
Q2 		$45.1M Buy
2,566,771
+448,919
+21% +$10.2M ﹤0.01% 2436
2021
Q1 		$53.4M Buy
2,117,852
+630,711
+42% +$12.3M ﹤0.01% 2278
2020
Q4 		$9.62M Buy
1,487,141
+185,983
+14% +$785K ﹤0.01% 3014
2020
Q3 		$3.34M Hold
1,301,158
– – ﹤0.01% 3331
2020
Q2 		$2.11M Sell
1,301,158
-99,591
-7% -$133K ﹤0.01% 3414
2020
Q1 		$1.46M Sell
1,400,749
-11,184
-0.8% -$15.2K ﹤0.01% 3383
2019
Q4 		$2.67M Buy
1,411,933
+36,090
+3% +$59.8K ﹤0.01% 3360
2019
Q3 		$1.49M Sell
1,375,843
-491,995
-26% -$698K ﹤0.01% 3541
2019
Q2 		$4.09M Buy
1,867,838
+30,191
+2% +$165K ﹤0.01% 3236
2019
Q1 		$11M Buy
1,837,647
+1,116,785
+155% +$7.4M ﹤0.01% 2769
2018
Q4 		$5.33M Sell
720,862
-468,312
-39% -$4.83M ﹤0.01% 3063
2018
Q3 		$17.3M Sell
1,189,174
-7,669
-0.6% -$131K ﹤0.01% 2648
2018
Q2 		$23.9M Buy
1,196,843
+29,414
+3% +$543K ﹤0.01% 2490
2018
Q1 		$20.5M Buy
1,167,429
+41,059
+4% +$870K ﹤0.01% 2490
2017
Q4 		$27.8M Sell
1,126,370
-57,504
-5% -$1.4M ﹤0.01% 2356
2017
Q3 		$30.6M Buy
1,183,874
+371,556
+46% +$9.96M ﹤0.01% 2296
2017
Q2 		$22M Buy
812,318
+100,799
+14% +$2.74M ﹤0.01% 2409
2017
Q1 		$21.2M Buy
711,519
+106,303
+18% +$3.07M ﹤0.01% 2417
2016
Q4 		$16.4M Buy
605,216
+179,729
+42% +$4.58M ﹤0.01% 2509
2016
Q3 		$10.9M Buy
425,487
+6,303
+2% +$134K ﹤0.01% 2648
2016
Q2 		$7.74M Buy
419,184
+249,888
+148% +$4.95M ﹤0.01% 2771
2016
Q1 		$3.21M Buy
169,296
+19,308
+13% +$369K ﹤0.01% 3183
2015
Q4 		$4.04M Buy
+149,988
New +$2.92M ﹤0.01% 3082

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group's ACRS Position: Q4 2025 in Review

Vanguard Group reduced its Aclaris Therapeutics (ACRS) stake by 0.21% in Q4 2025, selling an estimated $33.8K and leaving 6,502,080 shares worth $19.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2626.

Vanguard Group first reported a position in ACRS in Q4 2015 and has held it in 41 quarters since. The position peaked at $53.4M in Q1 2021. 122 funds tracked by Wall St. Rank hold ACRS as of Q4 2025.

  • Vanguard Group held 6,502,080 shares of Aclaris Therapeutics worth $19.6M as of Q4 2025.
  • Vanguard Group sold 13,378 Aclaris Therapeutics shares in Q4 2025, an estimated $33.8K.
  • Aclaris Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2626 holding.
  • Vanguard Group first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 41 quarters since.
  • Vanguard Group's Aclaris Therapeutics position peaked at $53.4M in Q1 2021.
  • 122 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.